, Tracking Stock Market Picks
Enter Symbol:
Rating: PCRX
Overweight $93

Pacira Pharmaceuticals Inc (NASDAQ: PCRX) upgraded to Overweight with price target $93 by Piper Jaffray

Tuesday,  Dec 15, 2015  4:25 PM ET by Betsy O'Brien Harrison

Piper Jaffray upgraded Pacira Pharmaceuticals Inc (NASDAQ: PCRX) to Overweight with price
target $93. Previously Piper Jaffray upgraded to Pacira Pharmaceuticals Inc (NASDAQ: PCRX) to Neutral on 08/07/2013, when the stock price was $35.40.

Pacira Pharmaceuticals, Inc. (Pacira), formerly Pacira, Inc., is the holding company for the Company?s California operating subsidiary of the same name, which it refers to as PPI-California. The Company is a specialty pharmaceutical company focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its product candidate EXPAREL is a long-acting bupivacaine (anesthetic/analgesic) product for postsurgical pain management. EXPAREL provides analgesia for up to 72 hours post-surgery. EXPAREL consists of bupivacaine encapsulated in DepoFoam. DepoFoam, its extended release drug delivery technology, is the basis for its commercial products: DepoCyt(e) and DepoDur, which it manufactures for its commercial partners. Its product portfolio and product candidate pipeline include EXPAREL, DepoCyt, DepoDur, DepoNSAID and DepoMethotrexate.

At Piper Jaffray, we understand there’s no substitute for relevant and timely research. That's why we provide: * fundamental and technical research * value-added investment ideas * market analysis With the information our research team provides, you’ll make better and more informed decisions for your portfolio.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy